EGFR and non-small cell lung carcinoma: Both erlotinib and gefitinib attenuated 2-NBDG uptake (Fig. 2b), glycolytic flux (Fig. 2c), and ATP levels (Fig. 2d) in TKI-sensitive (H292 and H322) but not in TKI-resistant (A549 and H460) EGFRWT-expressing cells, suggesting an essential role of glycolysis inhibition in the sensitivity to EGFR TKI in EGFRWT NSCLC cells.